Bruker (NASDAQ:BRKR) Issues Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Bruker (NASDAQ:BRKR) released its earnings results on Wednesday. The medical research company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.08, FiscalAI reports. The business had revenue of $823.40 million for the quarter, compared to the consensus estimate of $795.62 million. Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The firm’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period last year, the firm posted $0.47 earnings per share. Bruker updated its FY 2026 guidance to 2.100-2.150 EPS.

Here are the key takeaways from Bruker’s conference call:

• Q1 results beat expectations with reported revenue of $823.4M (+2.7% reported, organic -4.4%) and non‑GAAP EPS of $0.31, and management reconfirmed full‑year guidance of $3.57B–$3.60B revenue and $2.10–$2.15 non‑GAAP EPS.
• Order momentum strengthened—BSI organic bookings grew in the high single digits and book‑to‑bill stayed >1 for the third consecutive quarter—management expects a return to organic revenue growth in Q2 (low‑ to mid‑single digits).
• Several idiosyncratic, AI‑driven growth engines are accelerating performance, including semi‑metrology (now >$300M annual), SciY lab‑digitization/software (~$50M), security detection (~$70M), and large multi‑year BEST superconductor orders, which management says provide durable secular tailwinds.
• Margins were pressured in Q1 (non‑GAAP gross margin 50%, operating margin 10.2%) by FX, tariffs and mix, but management expects a 250–300 bp non‑GAAP operating margin expansion in 2026 driven by cost‑savings (now tracking ~$140M annualized), though execution and macro risks remain.

Bruker Stock Up 4.4%

BRKR traded up $1.86 on Thursday, reaching $44.16. 979,581 shares of the company traded hands, compared to its average volume of 2,280,838. The stock’s 50 day moving average price is $37.18 and its 200-day moving average price is $42.01. Bruker has a 52-week low of $28.53 and a 52-week high of $56.22. The company has a market cap of $6.72 billion, a price-to-earnings ratio of -293.75, a PEG ratio of 2.28 and a beta of 1.12. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.73 and a quick ratio of 0.87.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 23rd were given a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, March 23rd. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. Bruker’s payout ratio is presently -133.33%.

Insider Buying and Selling

In related news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total transaction of $79,800.00. Following the transaction, the vice president directly owned 128,443 shares of the company’s stock, valued at approximately $5,124,875.70. The trade was a 1.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 27.20% of the company’s stock.

Institutional Trading of Bruker

Several large investors have recently added to or reduced their stakes in the business. Pacer Advisors Inc. grew its position in Bruker by 42.8% in the fourth quarter. Pacer Advisors Inc. now owns 20,822 shares of the medical research company’s stock worth $981,000 after acquiring an additional 6,242 shares in the last quarter. Alberta Investment Management Corp bought a new stake in Bruker in the fourth quarter worth approximately $1,748,000. Mercer Global Advisors Inc. ADV bought a new stake in Bruker in the fourth quarter worth approximately $266,000. Utah Retirement Systems bought a new stake in Bruker in the fourth quarter worth approximately $257,000. Finally, Wellington Management Group LLP bought a new stake in Bruker in the fourth quarter worth approximately $8,172,000. 79.52% of the stock is owned by institutional investors.

Analysts Set New Price Targets

BRKR has been the topic of several analyst reports. Citigroup reissued a “neutral” rating on shares of Bruker in a research report on Thursday. Guggenheim dropped their target price on shares of Bruker from $58.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, March 30th. Barclays lifted their target price on shares of Bruker from $45.00 to $53.00 and gave the stock an “overweight” rating in a research report on Thursday. UBS Group reissued a “neutral” rating and issued a $45.00 target price on shares of Bruker in a research report on Thursday. Finally, TD Cowen reissued a “hold” rating on shares of Bruker in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $49.69.

Trending Headlines about Bruker

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Q1 beat consensus on both EPS and revenue: reported $0.31 EPS vs. $0.23 expected and $823.4M revenue vs. ~$795.6M expected — a clear short-term catalyst for the stock. Bruker: Q1 Earnings Snapshot
• Positive Sentiment: Management highlighted strong BSI (biopharma solutions) bookings and Europe growth that helped offset weaknesses, supporting near-term revenue momentum. BRKR Stock Up Post Q1 Earnings & Revenue Beat, Margins Down
• Neutral Sentiment: FY‑2026 guidance set at $2.10–$2.15 EPS and roughly $3.6B revenue — essentially in line with consensus (~$2.12 EPS). That removes surprise risk but offers limited upside from guidance alone.
• Neutral Sentiment: Management materials and full call transcript / slide deck are available for investors who want detail on segment trends and bookings. Bruker (BRKR) Q1 2026 Earnings Transcript Bruker Corporation 2026 Q1 – Results – Earnings Call Presentation
• Negative Sentiment: Margins are under pressure: operating and net margins compressed (company reported a slight negative net margin), which explains the EPS decline vs. prior year despite revenue growth — a watch item for profitability recovery. BRKR Stock Up Post Q1 Earnings & Revenue Beat, Margins Down
• Negative Sentiment: EPS declined year-over-year (from $0.47 a year ago to $0.31), driven by margin pressure and softer organic sales — signals investors should watch organic demand trends and margin remediation plans. Bruker (BRKR) Surpasses Q1 Earnings and Revenue Estimates

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.